

Response to Office Action  
U.S. Serial No. 09/954,789  
Attorney Docket No. 554912004910

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the Claims**

Claims 1-15 and 17-19: (canceled)

Claim 16 (currently amended): A kit of parts for use in sealing endoleaks arising from endovascular repair of an aneurysm which comprises:

- (a) a fluid composition which forms a coherent mass in the presence of blood which mass adheres to the vascular surface and/or the surface of the endovascular prosthesis wherein said fluid composition comprises a biocompatible solvent and a biocompatible polymer;
- (b) a catheter suitable for delivering the fluid composition to an endoleak site formed from endovascular repair of an abdominal aortic aneurysm;
- (c) a catheter suitable for delivering an endovascular prosthesis to the aneurysm; and
- (d) an endovascular prosthesis comprising a stent graft capable of inhibiting but not completely arresting blood flow into an the abdominal aortic aneurysm due to the presence of one or more endoleaks.

Claim 20 (previously presented): The kit of parts according to Claim 16 wherein said biocompatible polymer is selected from the group consisting of cellulose acetate polymers, ethylene vinyl alcohol copolymers and polyacrylates.

Claim 21 (previously presented): The kit of parts according to Claim 20 wherein said biocompatible polymer is a cellulose acetate polymer or an ethylene vinyl alcohol copolymer.

Response to Office Action  
U.S. Serial No. 09/954,789  
Attorney Docket No. 554912004910

Claim 22 (previously presented): The kit of parts according to Claim 16 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol, ethyl lactate, and acetone.

Claim 23 (previously presented): The kit of parts according to Claim 22 wherein said biocompatible solvent is dimethylsulfoxide.

Claim 24 (previously presented): The kit of parts according to Claim 16 wherein the fluid composition further comprises a contrast agent.

Claim 25 (previously presented): The kit of parts according to Claim 24 wherein said contrast agent is a water insoluble contrast agent.

Claim 26 (previously presented): The kit of parts according to Claim 25 wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum oxide, tungsten, and barium sulfate.

Claim 27 (previously presented): The kit of parts according to Claim 25 wherein said water insoluble contrast agent is characterized by having an average particle size of about 10  $\mu\text{m}$  or less.

Claim 28 (previously presented): The kit of parts according to Claim 24 wherein said contrast agent is a water soluble contrast agent.

Claim 29 (previously presented): The kit of parts according to Claim 28 wherein said water soluble contrast agent is selected from the group consisting of metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.

Response to Office Action  
U.S. Serial No. 09/954,789  
Attorney Docket No. 554912004910

Claim 30 (new): The kit of parts according to Claim 24 which further comprises:  
(e) a contrast agent dissolved in saline.

Claim 31 (new): The kit of parts according to Claim 30 wherein the contrast agent is iopamidol.

Claim 32 (new). The kit of parts according to Claim 16 wherein said one or more endoleaks arises from incomplete sealing at the interface of the aortic wall and the end of the prosthesis or from defects within the endovascular prosthesis.